Authors
Latest:
Dr. Schadendorf Discusses Sequencing Agents in MelanomaDirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.
Latest:
Selecting Optimal Therapy for Advanced Non-Clear Cell RCCFocusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.
Latest:
Dr. Davar on the Rationale for the Combination of Anti-TIM-3 and Anti-PD-1Diwakar Davar, MD, assistant professor of medicine, Department of Medicine, Hematology/Oncology, University of Pittsburgh, discusses the rationale for the combination of anti-TIM-3 and anti-PD-1 in multiple tumor types.
Latest:
Dr Zamarin on Recent Updates in Endometrial CancerDmitriy Zamarin, MD, PhD, discusses the most recent advances in gynecologic cancer management, particularly in endometrial cancer.
Latest:
Dr. Trombetta on Recurrent NRG1 Rearrangements in Invasive Mucinous AdenocarcinomaDomenico Trombetta, PhD, researcher, laboratory of oncology, Fondazione IRCCS Casa Sollievo della Sofferenza, discusses findings from an Italian multicenter cohort of patients with invasive mucinous adenocarcinoma, a rare histotype of lung adenocarcinoma.
Latest:
Dr. Bosse Discusses Bone-Targeted Agents in RCCDominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).
Latest:
Dr. Modest Discusses the German AIO KRK0110 Study in CRCDominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer.
Latest:
Those Women Who Changed My Life: Lessons Learned During a Surgical Oncology FellowshipThere is no such thing as a typical day for a breast surgical oncologist.
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Screening Breast Cancer Survivors: Do Mammograms work?Evidence that surveillance by mammogram in breast cancer survivors has been lacking until now
Latest:
Dr Dizon on the Future of Precision Medicine in Ovarian Cancer ManagementDon S. Dizon, MD, FACP, FASCO, discusses future directions for precision medicine approaches in ovarian cancer.
Latest:
Dr. Dizon on Potential Challenges for Patients With Gynecologic CancersDon S. Dizon, MD, FACP, FASCO, discusses potential challenges for patients with gynecologic cancers.
Latest:
Dr. Bergstrom on XMT-1536 in Ovarian CancerDonald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.
Latest:
Dr. Richards on Genetic Testing in Metastatic Pancreatic CancerDonald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.
Latest:
Dr. McDonald on the Continued Understanding of BevacizumabDr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
PROs Save Money, Lives, and Improve QoLDespite improved outcomes with new treatment and targeted therapies, patients with cancer continue to be afflicted by distressing symptoms and serious toxicities, which affect daily functioning and quality of life.
Latest:
Donna Berry on Patient CommunicationDonna L. Berry, PhD, RN, AOCN, FAAN, Director, Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, Associate Professor, Department of Medicine, Harvard Medical School, discusses using technology to communicate with patients
Latest:
Dr. Donna McNamara on PARP Inhibitors for Ovarian Cancer TreatmentDonna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.
